Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS)

Dalal, Deepan; Lin, Yih Chang; Brennan, Danielle M.; Borkar, Neil; Korman, Neil J.; Husni, M. Elaine

doi:10.1016/j.semarthrit.2015.01.003

Cited by 12 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with psoriasis and PsA often have comorbidities (CVD, psychiatric disease, IBD) and deleterious social behaviors (smoking/alcohol consumption) that can impact treatment decisions [22] and HRQoL [23, 24]. However, observations from PSOLAR indicate that a greater proportion of psoriasis patients self-reporting PsA had CVD compared with those with only psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry

et al. 2018

View full text Add to dashboard Cite

Background To evaluate demographics, family history, and previous medication use at enrollment in a subset of psoriasis patients with self-reported psoriatic arthritis (PsA) enrolled in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Methods PSOLAR is an international, prospective, longitudinal, disease-based registry that collects data in patients receiving, or are eligible to receive, systemic or biologic treatments for psoriasis. Baseline demographic, disease characteristics, medical history, and prior medication use at enrollment were evaluated in PSOLAR psoriasis patients self-reporting PsA ( n = 4315); a subset of which had their diagnosis of PsA established by a healthcare provider (HCP; n = 1719); patients with psoriasis only ( n = 7775); and the overall PSOLAR population ( n = 12,090). Results At enrollment, demographic characteristics were distinct between psoriasis patients self-reporting PsA and psoriasis only patients. Of the patients with psoriasis self-reporting PsA, 44.4% had cardiovascular disease (CVD), 26.3% had psychiatric illness, and 3.2% had inflammatory bowel disease (IBD), with each more prevalent than among patients with psoriasis only ( p < 0.001). Overall, 17.5% of psoriasis patients self-reporting PsA had a family history of PsA, 29.8% had used systemic steroids, 39.5% had used nonsteroidal anti-inflammatory drugs, and 83.5% had used biologics. Conclusions Demographics, family history, and previous medication use were generally comparable between “PsA established by a HCP” patients and psoriasis patients self-reporting PsA in the PSOLAR registry, but there were statistical differences compared with the psoriasis only group regarding the prevalence of certain comorbidities (CVD, psychiatric illness, and IBD). These analyses provide important data regarding characteristics of psoriasis patients with self-reported PsA in PSOLAR. Trial registration NCT00508547 . Electronic supplementary material The online version of this article (10.1186/s41927-018-0034-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Psoriatic arthritis (PsA) is a chronic heterogeneous inflammatory rheumatic disease involving peripheral arthritis, enthesitis, sacroiliitis, spondylitis, and extra‐articular manifestations, mainly psoriasis (Ps). The course of PsA varies from mild to severely damaged joints, causing physical and functional impairment, and diminished quality of life (QoL) . The goal of treatment is achieving a good QoL by controlling inflammation, reducing symptoms, and maintaining musculoskeletal function …”

Section: Introductionmentioning

confidence: 99%

Disease activity and functional status associated with health‐related quality of life and patient‐acceptable symptom state in patients with psoriatic arthritis in Thailand: A cross‐sectional study

et al. 2019

View full text Add to dashboard Cite

Aim:To identify factors associated with the EuroQol-5 Dimensions-5 levels (EQ-5D-5L) and patient acceptable symptom state (PASS) and to estimate health utility (HU) in Thai patients with psoriatic arthritis (PsA). Methods:A cross-sectional study of consecutive PsA patients visiting Siriraj Hospital was performed between 31 May, 2012 and 31 March, 2016. Data of patient demographics, HU outcomes (Thai EQ-5D-5L), disease activity (Disease Activity Index for Psoriatic Arthritis [DAPSA], the Clinical DAPSA [cDAPSA], the minimal disease activity [MDA]), and the Health Assessment Questionnaire (HAQ) were collected.Regression analyses were used to explore factors associated with each EQ-5D domain, HU, and PASS. Results:Of 129 PsA patients, the mean age was 47.6 years; 53.5% were male. The mean HU was 0.76. Univariable analysis showed lower disease activity and less impaired function were significantly associated with higher HU and no to mild problem in each EQ-5D domain. Multivariable analysis showed HAQ and disease activity indices (cDAPSA, DAPSA, MDA) adjusting for age, had good goodness-of-fit to HU (adjusted R 2 : 0.63-0.65). Patients answering "yes" to PASS had significantly longer disease duration of PsA, higher HU, lower disease activity, less disability, and were more often married than those answering "no" to PASS. Pain problem was the most important association to PASS adjusting for other domains and age. Conclusions:Disease activity and functional status in PsA patients were significant factors related to HU and PASS. To improve quality of life, the goal of treatment should be achieving remission, improving function, and controlling pain. K E Y W O R D ScDAPSA, EQ-5D-5L, MDA, PASS, psoriatic arthritis | 701 CHIOWCHANWISAWAKIT eT Al.

show abstract

“…The older the patient with plaque psoriasis, the longer the duration of the disease, the greater the BMI, the larger the size and severity of the lesions, and the higher the incidence of joint damage, results that have been well described in the literature. 11 , 31 , 32 In addition, we found that PASI and PEST significantly mediated between family history and DLQI in patients with type of plaque psoriasis, while other types such as guttate, pustular, and erythrodermic were not significant. Dilek Solmaz suggests that plaque psoriasis is more common in families with a history of psoriasis and suggests that the association between a family history of psoriasis/psoriatic arthritis and the pustular/plaque phenotype may indicate different genetic backgrounds and causative mechanisms in these subgroups.…”

Section: Discussionmentioning

confidence: 65%

“… 30 This idea coincides with Deepan S. Dalal, who found that despite aggressive treatment, patients with PsA had a poorer QoL compared to those with psoriasis. 31 Screening and early management treatment of PsA is therefore essential for patients diagnosed with psoriasis, and screening for early signs of mental illness is also needed to reduce the physical as well as psychological burden.…”

Section: Discussionmentioning

confidence: 99%

Relationship Between Family History and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study from China

Jiang,

Lu,

Wang

et al. 2024

CCID

View full text Add to dashboard Cite

Purpose The purpose of this study was to investigate the comprehensive impact of family history of psoriasis, lesion size, disease severity, and the possibility of joint involvement on patients’ quality of life(QoL). Patients and Methods Data from 5961 patients with psoriasis recruited from 440 hospitals throughout China were analyzed. The effects of family history of psoriasis, Body Surface Area(BSA), Psoriasis Area and Severity Index(PASI), and Psoriasis Epidemiology Screening Tool(PEST) on their Dermatology Life Quality Index(DLQI) were studied using a moderated chained mediated effects test. Results A total of 912 patients (15.30%) had a family history of psoriasis, and 5071 patients (85.10%) had plaque psoriasis. In patients with plaque psoriasis, the variables of family history, PASI, PEST, and DLQI were positively correlated with each other. Additionally, in patients with other types of psoriasis, PASI was positively correlated with PEST and DLQI. Age was positively correlated with PASI and PEST and negatively correlated with DLQI in patients with plaque psoriasis; their Body Mass Index(BMI) and disease duration were in positive correlation with PASI and PEST. The mediation effect of PASI and PEST between family history and DLQI was remarkable in patients with plaque psoriasis and not in those with other types of psoriasis. BSA moderated the association between family history and PASI in patients with plaque psoriasis. Conclusion PASI and PEST play a chain mediating role in the relationship between family history and DLQI in patients with plaque psoriasis, and high levels of BSA increase the ability of family history to positively predict PASI in plaque psoriasis, thereby affecting the patient’s QoL.

show abstract

Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS)

Cited by 12 publications

References 39 publications

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry

Disease activity and functional status associated with health‐related quality of life and patient‐acceptable symptom state in patients with psoriatic arthritis in Thailand: A cross‐sectional study

Relationship Between Family History and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study from China

Contact Info

Product

Resources

About